Jeff Lange

Mr. Lange has extensive experience in pharma and biotech licensing, collaborations, acquisitions and strategy. He was most recently VP Business Development at Samyang Biopharm USA where he led a business development, alliance management and project management team in Immuno-Oncology. He was previously VP Business Development - Valuation & Structuring at Baxalta where he led a team providing strategic input, deal structure, terms and valuation for in-licensing and M&A in immuno-oncology, hematology and immunology. Jeff previously spent two years at Glenmark Pharmaceuticals where he was VP, Licensing & Acquisitions, leading efforts in out-licensing an innovative pipeline of pre-clinical to Phase II, new chemical and biological entities in inflammatory/autoimmune and oncology indications. He was formerly the VP, Business Development for SciClone Pharmaceuticals, where he led out-licensing and market research for a portfolio of novel therapies in infectious disease, oncology, and oncology supportive care, as well as in-licensing and M&A for the established China-centric specialty pharma business. Jeff spent 15 years with Novartis, holding positions of increasing responsibilities, including Director of BD&L Finance, Head of Strategic Financial Panning - General Medicine, and Manager, Business Development and Planning.

Mr. Lange earned his MBA with a specialization in Finance and Concentrations in Strategy and Marketing from the University of Chicago. He earned his BBA in Accounting from the University of Iowa and is also a CPA.